Cronos Group Inc.

Listed Company

CRONCIK 0001656472NasdaqAcceleratedMedicinal Chemicals & Botanical ProductsA1CAFY ends Dec 31

Period

FY 2025

Revenue

$146.59M

Net Income

$-9.45M

Total Assets

$1.20B

Equity

$1.09B

Shares Out

379.05M

Op. Cash Flow

$25.87M

Business

Cronos Group Inc. is a global cannabinoid company that cultivates, manufactures and commercializes cannabis and cannabinoid-based consumer products. It offers adult-use and medical brands including Spinach®, Lord Jones® and PEACE NATURALS®, with products such as dried flower, pre-rolls, vaporizers, edibles, tinctures and topicals and also develops cultured cannabinoids through strategic partnerships. The company operates business units and consolidated joint ventures including Cronos GrowCo and Cronos Israel, and reports one consolidated segment covering Canada and Israel. Cronos distributes products through provincial cannabis control authorities, wholesale channels and strategic international partnerships in markets including Israel, Germany, the UK and Australia.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net revenue, before excise taxes	193	162	120	109	80
Excise taxes	−47	−44	−33	−23	−15
Net revenue	147	118	87	87	65
Cost of sales	83	92	75	71	70
Inventory write-down	654,000	707,000	805,000	0	12
Gross profit	63	25	12	15	−18
Sales and marketing	22	22	23	18	21
Research and development	4	4	6	13	22
General and administrative	42	47	49	68	91
Restructuring costs	2	630,000	2	4	0
Share-based compensation	7	9	9	15	10
Depreciation and amortization	2	4	5	6	4
Impairment loss on goodwill and indefinite-lived intangible assets	700,000	0	0	0	37,000
Impairment loss on long-lived assets	36,000	16	3	3	126
Total operating expenses	80	102	97	127	274
Operating loss	−17	−77	−85	−111	−292
Interest income, net	40	52	51	23	9
Share of income from equity method investments	0	2	2	3	−6
Gain on revaluation of loan receivable	0	12	0	0	—
Gain on revaluation of equity method investment	0	32	0	0	—
Loss on revaluation of financial instruments	−452,000	−6	−12	15	9
Impairment loss on other investments	0	−26	−23	−61	0
Foreign currency transaction gain (loss)	−29	58	−7	−2	0
Loss on held-for-sale assets	−6	−11	0	0	—
Change in allowance for credit loss on non-operating loan	−5	0	0	—	—
Other, net	−241,000	−301,000	1	−324,000	733,000
Total other income	275,000	113	11	−10	163
Income (loss) before income taxes	−17	37	−74	−121	−129
Income tax benefit	−14	−3	−3	34	−431,000
Income (loss) from continuing operations	−3	40	−70	−155	−128
Loss from discontinued operations	0	0	−4	−14	−269
Net income (loss)	−3	40	−75	−169	−397
Net income (loss) attributable to non-controlling interest	7	−1	−590,000	0	−1
Net income (loss) attributable to Cronos Group	−9	41	−74	−169	−396
Foreign exchange gain (loss) on translation	49	−86	22	−51	8
Comprehensive income (loss)	46	−46	−53	−219	−389
Comprehensive income (loss) attributable to non-controlling interest	9	−3	−526,000	46,000	229,000
Comprehensive income (loss) attributable to Cronos Group	37	−43	−52	−219	−389
Basic - continuing operations (in dollars per share)	−0.02	0.11	−0.18	−0.41	−0.34
Basic - discontinued operations (in dollars per share)	0	0	−0.01	−0.04	−0.73
Basic net income (loss) per share attributable to Cronos Group (in dollars per share)	−0.02	0.11	−0.19	−0.45	−1.07
Diluted - continuing operations (in dollars per share)	−0.02	0.11	−0.18	−0.41	−0.34
Diluted - discontinued operations (in dollars per share)	0	0	−0.01	−0.04	−0.73
Diluted net income (loss) per share attributable to Cronos Group (in dollars per share)	−0.02	0.11	−0.19	−0.45	−1.07

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	792	859	669	765	887
Short-term investments	40	0	192	113	118
Accounts receivable, net	34	15	14	23	22
Interest receivable	9	9	10	2	—
Other receivables	14	5	6	3	6
Current portion of loans receivable, net	0	618,000	6	9	5
Inventory, net	47	33	30	38	33
Prepaids and other current assets	8	6	5	7	9
Held-for-sale assets	0	8	0	—	0
Total current assets	944	936	933	960	1,080
Other investments	8	3	35	71	118
Non-current portion of loans receivable, net	21	16	69	72	81
Property, plant and equipment, net	146	133	59	61	74
Right-of-use assets	1	1	1	2	9
Goodwill	66	63	1	1	1
Intangible assets, net	9	11	21	27	18
Deferred tax assets	2	3	226,000	—	—
Total assets	1,197	1,166	1,140	1,213	1,398
Accounts payable	12	17	12	11	11
Income taxes payable	0	9,000	64,000	33	105,000
Accrued liabilities	36	32	28	22	26
Current portion of lease obligation	337,000	1	994,000	1	3
Derivative liabilities	0	40,000	102,000	15,000	14
Total current liabilities	48	50	41	68	54
Non-current portion due to non-controlling interests	733,000	1	1	1	—
Non-current portion of lease obligation	1	993,000	2	3	7
Deferred tax liabilities	4	4	181,000	0	81,000
Total liabilities	54	55	44	72	63
Share capital and additional paid-in capital (no par value; authorized for issue as of December 31, 2025 and 2024: unlimited; shares outstanding as of December 31, 2025 and 2024: 381,592,969 and 382,530,780, respectively)	663	670	662	611	595
Retained earnings	448	458	417	491	659
Accumulated other comprehensive loss	−17	−64	21	−797,000	50
Total equity attributable to shareholders of Cronos Group	1,094	1,064	1,100	1,144	1,337
Non-controlling interests	49	47	−3	−3	−3
Total shareholders equity	1,143	1,111	1,096	1,141	1,334
Total liabilities and shareholders equity	1,197	1,166	1,140	1,213	1,398

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation	7	9	9	15	10
Depreciation and amortization	14	9	8	13	15
Impairment loss on long-lived assets	36,000	16	4	3	—
Loss from investments	446,000	4	11	−18	−2
Changes in expected credit losses on long-term financial assets	5	1	−2	−662,000	12
Inventory step-up recorded to cost of sales	517,000	5	0	0	—
Other non-cash operating activities, net	1	−131,000	−2	1	335,000
Accounts receivable, net	−17	−917,000	9	−3	−13
Interest receivable	−11,000	−4	−14	−7	−2
Other receivables	−9	2	−1	1	3
Prepaids and other current assets	−2	−512,000	1	996,000	3
Inventory, net	−10	7	7	−7	12
Accounts payable	1	−7	−773,000	−863,000	−2
Income taxes payable	−10,000	−93,000	−33	34	−776,000
Accrued liabilities	2	3	5	−3	−5
Net cash provided by (used in) operating activities	26	19	−43	−89	−154
Purchase of short-term investments	−40	0	−608	−271	−120
Proceeds from short-term investments	0	186	533	269	215
Purchase of other investments	−5	0	0	—	—
Proceeds from sale of held for sale assets	3	0	0	—	3
Cash acquired in business combination	0	6	0	0	—
Advances on loans receivable	−13	−9	0	0	—
Proceeds from repayment on loans receivable	5	5	17	5	—
Dividends received from equity method investment	0	0	1	0	0
Dividend proceeds	0	0	345,000	384,000	0
Purchase of property, plant and equipment	−26	−12	−3	−3	−11
Purchase of intangible assets, net of disposals	−339,000	−743,000	−918,000	−2	−1
Other investing activities	0	0	860,000	68,000	3
Net cash provided by (used in) investing activities	−77	175	−59	−2	−29
Repurchases of common stock	−10	0	0	—	—
Dividend paid to non-controlling interest	−6	0	0	—	—
Withholding taxes paid on share-based awards	−4	−1	−1	−3	−13
Net cash used in financing activities	−20	−1	−1	−3	−13
Effect of foreign currency translation on cash and cash equivalents	4	−3	8	−29	5
Net change in cash and cash equivalents	−67	190	−95	−122	−191
Interest paid	0	0	0	0	0
Interest received	39	48	37	16	9
Income taxes paid	104,000	647,000	33	177,000	892,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro